Open AccessTYROSINE KINASE INHIBITORS OF THE EPIDERMAL GROWTH FACTOR RECEPTOR IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
Author(s) -
Svetlana Yu. Sletina,
Elena Poddubskaya
Publication year - 2018
Publication title -
rossijskij onkologičeskij žurnal
Language(s) - English
Resource type - Journals
eISSN - 2412-9119
pISSN - 1028-9984
DOI - 10.18821/1028-9984-2018-23-1-50-54
Subject(s) - epidermal growth factor receptor , lung cancer , tyrosine kinase , medicine , cancer research , oncology , epidermal growth factor , chemotherapy , cancer , lung , receptor
Considering the findings regarding the excellent frequency response (approximately 70%), survival without disease progression (median approximately of 9 months), better safety profile and the superior quality of life for patients compared with standard chemotherapy, EGFR TKIs in EGFR mutation positive non-small cell lung cancer patients can be now considered as first-line treatment in these patients. Evaluation of epidermal growth factor receptor mutations is necessary for all non-small cell lung cancer patients as the effective prognostic marker of the response to tyrosine kinase inhibitors of EGFR.